SEC Form 4 · accession 0001209191-15-021482
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Mar 2, 2015
Accepted (ET)
Mar 3, 2015 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $107.89 | Mar 2, 2015 | A | 17,000 | A | — | Mar 1, 2025 | Common stock | 17,000 | 137,000 | D |
Explanation of responses
- F1This option was granted on March 2, 2015. The shares underlying this option vest as to 25% of the underlying shares on March 2, 2016, with the remaining 75% vesting in 36 equal monthly installments thereafter.